Author

Y. Saiki

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan　- The Third Official Report From J-MACS.

BACKGROUND The nationwide impact in Japan of contemporary improvement in the clinical management of durable left ventricular assist device (LVAD), together with the introduction of the HeartMate 3 (Abbott, Pleasanton, CA, USA), on clinical outcomes remains uncertain. METHODS AND RESULTS Using the Japanese Registry fo...

Teruhiko Imamura, K. Kinugawa, Takashi Nishimura et al. · Circulation Journal · 0 citations

Open access Aug 2026

Short- and Long-Term Days Alive and Out of Hospital After Left Ventricular Assist Device Implantation.

BACKGROUND Durable left ventricular assist devices (LVADs) improve the outcomes of patients with advanced heart failure; however, recurrent hospitalization remains a major burden. The days alive and out of hospital (DAOH) is a patient-centered metric that reflects both survival and hospitalization burden; however, data...

Toru Kondo, S. Kazama, Takahiro Imaizumi et al. · Journal of the American Hear... · 0 citations

Open access Jul 2026

Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan.

This nationwide real-world study provides the first validation of a nationally mandated DT eligibility algorithm and may support risk-based clinical decision-making in Japanese DT practice.

Teruhiko Imamura, K. Kinugawa, Takashi Nishimura et al. · JACC: Asia · 1 citation

Y. Saiki

Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan - The Third Official Report From J-MACS.

Short- and Long-Term Days Alive and Out of Hospital After Left Ventricular Assist Device Implantation.

Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan.

Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan　- The Third Official Report From J-MACS.